Evodia rutaecarpa for Health & Longevity - Quick Reference Sheet

Evodia rutaecarpa for Health & Longevity

Created on 10/13/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Wonder 1.0 – Audit

Evodia rutaecarpa is a dried fruit used in East Asian herbal practice, sold as a herbal supplement for pain, digestive upset, weight, circulation, and healthy ageing. Human evidence is exceptionally thin: weight change occurred without a clear advantage for the fruit, and all other claimed benefits rest on animal or cell findings. Liver, heart, and medicine-interaction concerns remain unresolved, with no demonstrated relevance to longevity in people. (Full Review)

Protocol

No established longevity protocol
No established dose
No clinical guideline establishes dose, duration, or target outcome for health and longevity use
Human trial regimen
Evodiamine 6.75 mg and rutaecarpine 0.66 mg
Capsules alongside a low-calorie diet for eight weeks
Traditional decoction amount
3–9 g of berries
Decoction divided into two or three servings daily
Time to effect
Time to effect
Not established in humans
Only trial assessed outcomes after four and eight weeks of dieting

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • People with liver disease or unexplained raised liver enzymes
  • Children and adolescents
  • People scheduled for surgery
Key Interactions
  • Medicines cleared by CYP1A2 (caffeine, theophylline)
  • Medicines cleared by CYP2C9 or CYP2D6 (warfarin, metoprolol)
  • Medicines cleared by CYP3A4 (simvastatin, midazolam)
  • Blood-pressure-lowering medicines (amlodipine, losartan) and supplements
  • Caffeine and stimulant supplements
  • Over-the-counter pain and cold medicines (ibuprofen, dextromethorphan)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Liver Injury; Gastrointestinal Irritation; Warmth and Flushing Symptoms
  • Speculative: Heart Toxicity; Harm From Isolated High-Dose Alkaloids

Monitoring

Marker Target Why
Alanine aminotransferase 7–56 units per litre (standard reference range) Safety check — stops or changes use
Aspartate aminotransferase 10–40 units per litre (standard reference range) Safety check — stops or changes use
Total bilirubin (a breakdown product cleared by the liver) 0.1–1.2 mg/dL (standard reference range) Safety check — stops or changes use
Blood pressure No established target — track change from personal baseline instead Safety and expected-change marker
Resting heart rate 60–100 beats per minute (standard reference range) Safety check — changes use
Body weight No established target — track change from personal baseline instead Expected-change marker

Cadence: Liver tests and blood-pressure checks at one month, then every three to six months; trial assessment at four and eight weeks

Qualitative Assessment

  • Warmth and flushing: Frequency and intensity of heat sensation or flushing after use
  • Digestive symptoms: Nausea, stomach pain, vomiting, or diarrhoea frequency
  • Pain and headache: Headache or pain days per week, recorded consistently
  • Energy and sleep: Perceived energy and sleep quality, especially with caffeine use